Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, C Hoeller, NI Khushalani, Miller WH Jr, CD Lao, GP Linette, L Thomas, P Lorigan, KF Grossmann, JC Hassel, M Maio, M Sznol, PA Ascierto, P Mohr, B ChmielowskiA Bryce, IM Svane, JJ Grob, AM Krackhardt, C Horak, A Lambert, AS Yang, J. Larkin

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Pages (from-to)375-384
    JournalThe Lancet Oncology
    Volume16
    Issue number4
    DOIs
    Publication statusPublished - 18 Mar 2015

    Cite this